The induction of type i interferon production in hepatitis C-infected patients

Lawrence Pfeffer, Margaret A. Madey, Caroline A. Riely, Jaquelyn F. Fleckenstein

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Chronic infection with hepatitis C virus (HCV) is a major global health problem. One way HCV may evade the host immune response is by inhibiting the production of type I interferon (IFN). In addition, the standard treatment for chronic HCV infection involves treatment with IFN- (or its pegylated derivative), alone or in combination with ribavirin. Therefore, it is believed that an important reason that most HCV-infected individuals progress from acute to chronic infection is due to a defect in the host response. In this study, we examined the host response to HCV infection in a cohort of patients enrolled in the UTHSC Cooperative HCV Research Center by determining levels of biologically active IFN in the sera of patients. We found that 15 of 35 enrolled HCV-infected patients show serum levels of IFN (ranging from 2 to 40 IU/mL) before initiation of therapy. Uninfected individuals do not have circulating levels of IFN. Basal IFN levels do not correlate with the clinical response to therapy, nor do they reflect the age, sex, or race of patients. These results suggest that the differential response of patients most likely reflects a defect in the later stages of the host innate immune response, such as the cellular response to endogenous or exogenous IFN. In contrast, the early stage of the host immune response in vivo of many HCV-infected patients (∼40%) is intact as determined by IFN production.

Original languageEnglish (US)
Pages (from-to)299-306
Number of pages8
JournalJournal of Interferon and Cytokine Research
Volume29
Issue number5
DOIs
StatePublished - May 1 2009

Fingerprint

Hepatitis C
Hepacivirus
Interferons
Virus Diseases
Interferon Type I
Ribavirin
Chronic Hepatitis C
Therapeutics
Infection
Serum
Innate Immunity
Research

All Science Journal Classification (ASJC) codes

  • Immunology
  • Virology
  • Cell Biology

Cite this

The induction of type i interferon production in hepatitis C-infected patients. / Pfeffer, Lawrence; Madey, Margaret A.; Riely, Caroline A.; Fleckenstein, Jaquelyn F.

In: Journal of Interferon and Cytokine Research, Vol. 29, No. 5, 01.05.2009, p. 299-306.

Research output: Contribution to journalArticle

Pfeffer, Lawrence ; Madey, Margaret A. ; Riely, Caroline A. ; Fleckenstein, Jaquelyn F. / The induction of type i interferon production in hepatitis C-infected patients. In: Journal of Interferon and Cytokine Research. 2009 ; Vol. 29, No. 5. pp. 299-306.
@article{af5bf1d16b664caaa77fddf3dda15335,
title = "The induction of type i interferon production in hepatitis C-infected patients",
abstract = "Chronic infection with hepatitis C virus (HCV) is a major global health problem. One way HCV may evade the host immune response is by inhibiting the production of type I interferon (IFN). In addition, the standard treatment for chronic HCV infection involves treatment with IFN- (or its pegylated derivative), alone or in combination with ribavirin. Therefore, it is believed that an important reason that most HCV-infected individuals progress from acute to chronic infection is due to a defect in the host response. In this study, we examined the host response to HCV infection in a cohort of patients enrolled in the UTHSC Cooperative HCV Research Center by determining levels of biologically active IFN in the sera of patients. We found that 15 of 35 enrolled HCV-infected patients show serum levels of IFN (ranging from 2 to 40 IU/mL) before initiation of therapy. Uninfected individuals do not have circulating levels of IFN. Basal IFN levels do not correlate with the clinical response to therapy, nor do they reflect the age, sex, or race of patients. These results suggest that the differential response of patients most likely reflects a defect in the later stages of the host innate immune response, such as the cellular response to endogenous or exogenous IFN. In contrast, the early stage of the host immune response in vivo of many HCV-infected patients (∼40{\%}) is intact as determined by IFN production.",
author = "Lawrence Pfeffer and Madey, {Margaret A.} and Riely, {Caroline A.} and Fleckenstein, {Jaquelyn F.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1089/jir.2008.0092",
language = "English (US)",
volume = "29",
pages = "299--306",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - The induction of type i interferon production in hepatitis C-infected patients

AU - Pfeffer, Lawrence

AU - Madey, Margaret A.

AU - Riely, Caroline A.

AU - Fleckenstein, Jaquelyn F.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Chronic infection with hepatitis C virus (HCV) is a major global health problem. One way HCV may evade the host immune response is by inhibiting the production of type I interferon (IFN). In addition, the standard treatment for chronic HCV infection involves treatment with IFN- (or its pegylated derivative), alone or in combination with ribavirin. Therefore, it is believed that an important reason that most HCV-infected individuals progress from acute to chronic infection is due to a defect in the host response. In this study, we examined the host response to HCV infection in a cohort of patients enrolled in the UTHSC Cooperative HCV Research Center by determining levels of biologically active IFN in the sera of patients. We found that 15 of 35 enrolled HCV-infected patients show serum levels of IFN (ranging from 2 to 40 IU/mL) before initiation of therapy. Uninfected individuals do not have circulating levels of IFN. Basal IFN levels do not correlate with the clinical response to therapy, nor do they reflect the age, sex, or race of patients. These results suggest that the differential response of patients most likely reflects a defect in the later stages of the host innate immune response, such as the cellular response to endogenous or exogenous IFN. In contrast, the early stage of the host immune response in vivo of many HCV-infected patients (∼40%) is intact as determined by IFN production.

AB - Chronic infection with hepatitis C virus (HCV) is a major global health problem. One way HCV may evade the host immune response is by inhibiting the production of type I interferon (IFN). In addition, the standard treatment for chronic HCV infection involves treatment with IFN- (or its pegylated derivative), alone or in combination with ribavirin. Therefore, it is believed that an important reason that most HCV-infected individuals progress from acute to chronic infection is due to a defect in the host response. In this study, we examined the host response to HCV infection in a cohort of patients enrolled in the UTHSC Cooperative HCV Research Center by determining levels of biologically active IFN in the sera of patients. We found that 15 of 35 enrolled HCV-infected patients show serum levels of IFN (ranging from 2 to 40 IU/mL) before initiation of therapy. Uninfected individuals do not have circulating levels of IFN. Basal IFN levels do not correlate with the clinical response to therapy, nor do they reflect the age, sex, or race of patients. These results suggest that the differential response of patients most likely reflects a defect in the later stages of the host innate immune response, such as the cellular response to endogenous or exogenous IFN. In contrast, the early stage of the host immune response in vivo of many HCV-infected patients (∼40%) is intact as determined by IFN production.

UR - http://www.scopus.com/inward/record.url?scp=66749118387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749118387&partnerID=8YFLogxK

U2 - 10.1089/jir.2008.0092

DO - 10.1089/jir.2008.0092

M3 - Article

VL - 29

SP - 299

EP - 306

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 5

ER -